NCT06295952 2026-03-04
A Study of Pasireotide in People With Prolactinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
26 trialsNCT01313559 2025-04-30
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT06456359 2025-01-13
PAMSARC
University Hospital Heidelberg
Phase 2 Recruiting
NCT04826432 2024-02-08
PASIREOCHIP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT01253161 2023-03-06
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02215070 2021-11-17
Pasireotide in Prevention of GI Toxicity
Duke University
Phase 2 Completed
NCT03053284 2021-05-14
Pasireotide in Hyperinsulinemic Hypoglycemia
Montefiore Medical Center
Phase 2 Withdrawn
NCT01563354 2021-04-02
LUNA
Novartis
Phase 2 Completed
NCT01270321 2021-02-17
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Emory University
Phase 2 Completed
NCT01915303 2020-09-18
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Novartis
Phase 2 Terminated
NCT01673646 2019-09-16
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Novartis
Phase 2 Completed
NCT02021942 2018-02-05
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
University of Regensburg
Phase 2 Completed
NCT02780882 2018-01-26
SOM230 Ectopic ACTH-producing Tumors
Cedars-Sinai Medical Center
Phase 2 Withdrawn
NCT00929669 2017-11-28
LAR
University of Pennsylvania
Phase 2 Terminated
NCT01252251 2017-08-01
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01639352 2017-07-12
Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Completed
NCT01356862 2017-01-25
SOM 230
Alliance Pour La Recherche en Cancerologie
Phase 2 Completed
NCT01617733 2016-11-02
Pasireotide Therapy in Patients With Nelson's Syndrome
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT00958841 2016-07-26
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Novartis
Phase 2 Terminated
NCT01625520 2016-04-25
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
Federico II University
Phase 2 Completed
NCT01488487 2016-04-07
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01329289 2016-02-12
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
University of Pittsburgh
Phase 2 Withdrawn
NCT00813592 2014-06-11
Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
University of Utah
Phase 2 Terminated
NCT01234974 2013-01-10
IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus
Milton S. Hershey Medical Center
Phase 2 Withdrawn
NCT00088595 2012-06-04
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Novartis
Phase 2 Completed
NCT01417806 2011-08-16
Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer
South Florida Veterans Affairs Foundation for Research and Education
Phase 2 Unknown